Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Waypoint Bio›
News
AddedJun 1, 2026
UpdatedJun 1, 2026
Waypoint Bio

Waypoint Bio

Series A

Waypoint Bio engineers AI-designed CAR T therapies for solid tumors using spatial biology.

HQ
New York, NY, US
Founded
2024
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Latest News About Waypoint Bio

Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China

Endpoints News

Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China

New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China. The...

May 27, 2026

Waypoint Bio Appoints Meta NeuroAI Pioneer Patrick Kaifosh as Chief Technology Officer

Waypoint Bio

Waypoint Bio Appoints Meta NeuroAI Pioneer Patrick Kaifosh as Chief Technology Officer

Waypoint Bio is excited to welcome Patrick Kaifosh, Ph.D., as its new Chief Technology Officer. Dr. Kaifosh brings a track record of...

Oct 21, 2025

Top 10 Spatial Biology Companies of 2024

GEN

Top 10 Spatial Biology Companies of 2024

Waypoint Bio was named as an up and comer in GEN's Top 10 Spatial Biology Companies of 2024 list, recognizing the company's innovative...

Oct 1, 2024

Waypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology

BusinessWire

Waypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology

Waypoint Bio, a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology,...

Jun 28, 2024

Waypoint Bio Launches with $14.5 Million Seed Financing

LinkedIn

Waypoint Bio Launches with $14.5 Million Seed Financing

Today we announced the close of a $14.5 million seed financing, led by Hummingbird Ventures, to turbocharge drug discovery using in vivo...

Jun 28, 2024